|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvalYear
|
2009
|
|
gptkbp:approvedBy
|
gptkb:United_States
|
|
gptkbp:ATCCode
|
A10BH03
|
|
gptkbp:bioavailability
|
75%
|
|
gptkbp:brand
|
Onglyza
|
|
gptkbp:CASNumber
|
361442-04-8
|
|
gptkbp:chemicalFormula
|
contains a cyanopyrrolidine group
|
|
gptkbp:contraindication
|
history of pancreatitis
hypersensitivity to saxagliptin
|
|
gptkbp:developer
|
gptkb:AstraZeneca
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:drugClass
|
DPP-4 inhibitor
|
|
gptkbp:eliminationHalfLife
|
2.5 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:hasMolecularFormula
|
C18H25N3O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
saxagliptin
|
|
gptkbp:interactsWith
|
CYP3A4 inhibitors
CYP3A4 inducers
|
|
gptkbp:KEGGID
|
D08913
|
|
gptkbp:legalStatus
|
prescription only
patent expired in US
|
|
gptkbp:mechanismOfAction
|
inhibits dipeptidyl peptidase-4
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:monitors
|
blood glucose
renal function
|
|
gptkbp:notRecommendedFor
|
gptkb:diabetic_ketoacidosis
type 1 diabetes
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
11243994
DB06335
|
|
gptkbp:riskFactor
|
may increase risk of heart failure
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:hypoglycemia
headache
urinary tract infection
upper respiratory tract infection
|
|
gptkbp:UNII
|
MGR1I0Y2RF
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes_mellitus
|
|
gptkbp:bfsParent
|
gptkb:Kombiglyze_XR
gptkb:Qtern
gptkb:Qternmet_XR
gptkb:DPP-4_enzyme
gptkb:DPP-4_inhibitors
|
|
gptkbp:bfsLayer
|
7
|